We have shown that sustained lipogenesis through the maintenance of active SREBP-1 is a key feature of therapy resistance to vemurafenib in BRAF-mutant melanoma, and that inhibition of SREBP-1 sensitizes melanoma to targeted therapy. Here, SREBF1 is linked to melanoma.